HHS.gov

HHS Winds Down mRNA Vaccine Development Under BARDA

BBC News

RFK Jr cancels $500m in mRNA vaccine development in the US

Sky News

RFK Jr announces US is scrapping $500m of vaccine projects

FOX News

RFK Jr cancels $500 million in mRNA research, HHS to prioritize 'safer' vaccine alternatives

Breitbart

Kennedy ends federal mRNA vaccine projects over experts objections

SecKennedy

chrismeekins

JimFergusonUK

drsimonegold

<h2></h2>

The U.S. Department of Health and Human Services announced Tuesday the termination of 22 mRNA vaccine development contracts worth approximately $500 million under the Biomedical Advanced Research and Development Authority (BARDA).

The U.S. Department of Health and Human Services announced Tuesday the termination of 22 mRNA vaccine development contracts worth approximately $500 million under the Biomedical Advanced Research and Development Authority (BARDA).

Health Secretary Robert F. Kennedy Jr. stated that BARDA is terminating the investments because data show that these vaccines fail to provide effective protection against upper respiratory infections, such as COVID-19 and the flu.

Health Secretary Robert F. Kennedy Jr. stated that BARDA is terminating the investments because data show that these vaccines fail to provide effective protection against upper respiratory infections, such as COVID-19 and the flu.

The cancellations affect contracts with major pharmaceutical companies, including Pfizer, Moderna, Sanofi Pasteur, CSL Seqirus, and Gritstone, as well as academic institutions like Emory University and Tiba Biotech.

The cancellations affect contracts with major pharmaceutical companies, including Pfizer, Moderna, Sanofi Pasteur, CSL Seqirus, and Gritstone, as well as academic institutions like Emory University and Tiba Biotech.

Some final-stage contracts with companies like Arcturus and Amplitude will be allowed to run their course to preserve prior taxpayer investment. However, no new mRNA-based projects will be initiated.

Some final-stage contracts with companies like Arcturus and Amplitude will be allowed to run their course to preserve prior taxpayer investment. However, no new mRNA-based projects will be initiated.

HHS stated that it will shift funding toward what it calls "safer, broader vaccine platforms," such as "whole virus vaccines and novel platforms that don't collapse when viruses mutate."

The Associated Press

HHS stated that it will shift funding toward what it calls "safer, broader vaccine platforms," such as "whole virus vaccines and novel platforms that don't collapse when viruses mutate."

The department clarified that this announcement does not impact other uses of mRNA technology within HHS, and existing approved mRNA vaccines for COVID-19 and RSV remain unaffected.

The department clarified that this announcement does not impact other uses of mRNA technology within HHS, and existing approved mRNA vaccines for COVID-19 and RSV remain unaffected.

HHS.gov #

BBC News #

Sky News #

FOX News #

Breitbart #

Health Secretary Robert F. Kennedy Jr. stated that BARDA is terminating the investments because data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu.</span

Health Secretary Robert F. Kennedy Jr. stated that BARDA is terminating the investments because data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu.

The cancellations affect contracts with major pharmaceutical companies including Pfizer, Moderna, Sanofi Pasteur, CSL Seqirus, and Gritstone, as well as academic institutions like Emory University and Tiba Biotech.</span

The Associated Press #

The cancellations affect contracts with major pharmaceutical companies including Pfizer, Moderna, Sanofi Pasteur, CSL Seqirus, and Gritstone, as well as academic institutions like Emory University and Tiba Biotech.

Some final-stage contracts with companies like Arcturus and Amplitude will be allowed to run their course to preserve prior taxpayer investment, while no new mRNA-based projects will be initiated.</span

Some final-stage contracts with companies like Arcturus and Amplitude will be allowed to run their course to preserve prior taxpayer investment, while no new mRNA-based projects will be initiated.

HHS stated it will shift funding toward what it calls safer, broader vaccine platforms like whole-virus vaccines and novel platforms that remain effective as viruses mutate.</span

HHS stated it will shift funding toward what it calls safer, broader vaccine platforms like whole-virus vaccines and novel platforms that remain effective as viruses mutate.

The department clarified that other uses of mRNA technology within HHS are not impacted by this announcement, and existing approved mRNA vaccines for COVID-19 and RSV remain unaffected.</span

The department clarified that other uses of mRNA technology within HHS are not impacted by this announcement, and existing approved mRNA vaccines for COVID-19 and RSV remain unaffected.

Canceling these contracts undermines pandemic preparedness and abandons one of our most promising medical tools. mRNA technology saved millions of lives during COVID-19 and offers rapid vaccine development crucial for future pandemics. This move weakens our defense against biological threats.

Canceling these contracts undermines pandemic preparedness and abandons one of our most promising medical tools. mRNA technology saved millions of lives during COVID-19 and offers rapid vaccine development crucial for future pandemics. This move weakens our defense against biological threats.

HHS Cancels $500M in mRNA Vaccine Development Contracts

Health

United States of America

Vaccination

This decision is a necessary course correction based on scientific evidence. The data clearly show mRNA vaccines don't provide adequate protection against respiratory infections, and they become ineffective when viruses mutate. It's time to invest in proven, safer vaccine platforms that offer broader protection.

This decision is a necessary course correction based on scientific evidence. The data clearly show mRNA vaccines don't provide adequate protection against respiratory infections, and they become ineffective when viruses mutate. It's time to invest in proven, safer vaccine platforms that offer broader protection.

Canceling these contracts undermines pandemic preparedness and abandons one of America's most promising medical tools. mRNA technology saved millions of lives during COVID-19 and offers rapid vaccine development crucial for future pandemics. This move weakens our defense against biological threats.

Canceling these contracts undermines pandemic preparedness and abandons one of America's most promising medical tools. mRNA technology saved millions of lives during COVID-19 and offers rapid vaccine development crucial for future pandemics. This move weakens our defense against biological threats.

National Post

Health experts slam RFK Jr.'s 'dangerous decision' to cut US$500M in funding for mRNA vaccine development

There's a 40% chance that the FDA will approve a seasonal influenza vaccine for the 2025-2026 flu season before Oct. 1, 2025, according to the Metaculus prediction community.

There's a 40% chance that the FDA will approve a seasonal influenza vaccine for the 2025-2026 flu season before Oct. 1, 2025, according to the Metaculus prediction community.

HHS Cancels $500M in mRNA Vaccine Development Contracts

HHS Cancels $500M in mRNA Vaccine Development Contracts

The Spin

Metaculus Prediction

Articles on this story

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

HHS Cancels $500M in mRNA Vaccine Development Contracts

HHS Cancels $500M in mRNA Vaccine Development Contracts

The Spin

Metaculus Prediction

Articles on this story

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters